Forma Therapeutics Holdings, Inc. (FMTX)
Stock Price:
$49.50 USD
5.77 (13.19%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.04B |
| Revenue (ttm) |
10.82M |
| Net Income (ttm) |
n/a |
| Shares Out |
41.12M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 25, 2020 |
| Last Price |
$49.50 |
| Previous Close |
$43.73 |
| Change ($) |
5.77 |
| Change (%) |
13.19% |
| Day's Open |
43.44 |
| Day's Range |
42.83 - 52.09 |
| Day's Volume |
297,688 |
| 52-Week Range |
31.45 - 52.09 |
More Stats
| Market Cap |
2.04B |
| Enterprise Value |
1.62B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
41.12M |
| Float |
32.00M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
999,717 |
| Short Ratio |
4.53 |
| Short % of Float |
1.84% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
188.09 |
| PB Ratio |
4.35 |
| Revenue |
10.82M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
414.30M |
| Net Cash / Share |
10.08 |
| Gross Margin |
-99.42% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$56.25*
(13.64% upside)
Low
53.0
Current: $49.50
High
64.0
Target: 56.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 101 | 164 |
| Revenue Growth | -38.72% | - |
| Gross Profit | 101 | 164 |
| Operating Income | -40.45 | 9.69 |
| Net Income | -34.79 | 5.29 |
| Shares Outstanding | 10.90 | 10.90 |
| Earnings Per Share | -4.93 | -0.04 |
| Operating Cash Flow | -34.49 | -133 |
| Capital Expenditures | -0.53 | -3.39 |
| Free Cash Flow | -35.02 | -136 |
| Cash & Equivalents | 173 | 152 |
| Net Cash / Debt | 173 | 152 |
| Assets | 183 | 263 |
| Liabilities | 26.66 | 246 |
| Book Value | 18.25 | -48.87 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Forma Therapeutics Holdings, Inc. |
| Country |
United States |
| Employees |
80 |
| CEO |
Frank D. Lee |
Stock Information
| Ticker Symbol |
FMTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FMTX |
| IPO Date |
June 19, 2020 |
Description
Forma Therapeutics Holdings, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.